Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh · Delayed Price · Currency is BDT 217.30
+0.10 (0.05%)
At close: Jan 22, 2026
DSE:SQURPHARMA Revenue
Square Pharmaceuticals PLC. had revenue of 21.59B BDT in the quarter ending September 30, 2025, with 21.64% growth. This brings the company's revenue in the last twelve months to 80.13B, up 14.41% year-over-year. In the fiscal year ending June 30, 2025, Square Pharmaceuticals PLC. had annual revenue of 76.29B with 8.83% growth.
Revenue (ttm)
80.13B
Revenue Growth
+14.41%
P/S Ratio
2.40
Revenue / Employee
5.03M
Employees
15,937
Market Cap
192.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 76.29B | 6.19B | 8.83% |
| Jun 30, 2024 | 70.10B | 9.39B | 15.47% |
| Jun 30, 2023 | 60.71B | 3.11B | 5.40% |
| Jun 30, 2022 | 57.60B | 6.89B | 13.60% |
| Jun 30, 2021 | 50.70B | 4.83B | 10.52% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beximco Pharmaceuticals PLC. | 46.34B |
| Renata | 44.03B |
| The ACME Laboratories | 37.48B |
| The IBN SINA Pharmaceutical Industry | 12.84B |
| Beacon Pharmaceuticals | 11.58B |
| Navana Pharmaceuticals | 9.52B |
| Unilever Consumer Care | 3.63B |
| Techno Drugs | 3.23B |